

In the Claims:

Please replace all prior versions, and listings, of claims in the application with the following list of claims.

1. (Currently amended) An isolated monovalent antibody or antigen-binding fragment thereof that specifically binds to ~~MGFR~~ MUC1 Growth Factor Receptor (MGFR).

2. (Canceled)

3. (Canceled)

4. (Currently amended) An isolated antibody or antigen-binding fragment thereof as recited in claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to ~~PSMGFR~~ Primary Sequence of the MUC1 Growth Factor Receptor (PSMGFR).

5. (Currently amended) An isolated antibody or antigen-binding fragment thereof as recited in ~~claim 4~~ claim 1, wherein the antibody or antigen-binding fragment thereof specifically binds to the amino acid sequence set forth in SEQ ID NO: 36 ~~or a functional variant or fragment thereof~~ ; a functional variant of SEQ ID NO: 36; or a fragment of SEQ ID NO: 36, comprising up to 15 amino acid additions or deletions at its N-terminus and comprising up to 20 amino acid substitutions.

6. (Currently amended) An isolated antibody or antigen-binding fragment thereof as recited in claim 5, wherein the antibody or antigen-binding fragment thereof specifically binds to the amino acid sequence set forth in SEQ ID NO:36 ~~or a functional variant or fragment thereof~~ ; a functional variant of SEQ ID NO: 36; or a fragment of SEQ ID NO: 36, comprising up to 10 amino acid substitutions.

7-12. (canceled)

13. (Previously presented) A composition comprising the antibody or antigen-binding fragment of claim 1.

14. (Previously presented) The composition as recited in claim 13, which is a pharmaceutical composition and further comprises a pharmaceutically acceptable carrier.

15-16. (canceled)

17. (Previously presented) A kit comprising: the antibody or antigen-binding fragment thereof according to claim 1.

18-26. (canceled)

27. (Withdrawn) A method comprising: providing a peptide including a portion of a cell surface receptor that interacts with an activating ligand such as a growth factor to promote cell proliferation, the portion including enough of the cell surface receptor to interact with the activating ligand and the portion; and generating a antibody or antigen-binding fragment thereof that specifically binds to the peptide.

28-56. (Canceled)

57. (Withdrawn) A method of determining the aggressiveness and/or metastatic potential of a cancer comprising: contacting a sample obtained from a subject having or suspected of having the cancer with an antibody or antigen-binding fragment thereof that specifically binds to a peptide expressed on a cell surface; and determining an amount of the antibody or antigen-binding fragment thereof that specifically binds to the sample.

58. (Withdrawn) A method as recited in claim 57, wherein the sample comprises cells of the subject and/or a solubilized lysate thereof.

59. (Withdrawn)      A method as recited in claim 57, wherein the peptide includes a portion of a cell surface receptor that interacts with an activating ligand such as a growth factor to promote cell proliferation, the portion including enough of the cell surface receptor to interact with the activating ligand.

60. (Withdrawn)      A method as recited in claim 57, wherein the antibody or antigen-binding fragment thereof is immobilized relative to or adapted to be immobilized relative to a signaling entity.

61. (Withdrawn)      A method as recited in claim 60, wherein the antibody or antigen-binding fragment thereof is bivalent.

62. (Withdrawn)      A method as recited in claim 59, wherein the cell surface receptor is MUC1.

63-195. (Canceled)